Evaluation of a Preventive Therapeutic Strategy for Postpartum Venous Thromboembolism in Women With Genetic Risk Factor
Key facts
- Who runs it
- Hospices Civils de Lyon
- Where
- France2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 86 people enrolled
- Started
- 4 Feb 2026
- Ended
- 13 Mar 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- Retrospective collection of health data
- Phone call to every participant
- Record updated
- 6 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Age > 18
- Heterozygous asymptomatic Factor V Leiden mutation or Factor II mutation, diagnosed before or during pregnancy
- Delivering between 01/01/2020 and 31/12/2025
- Patient with French social security rights
Who cannot take part
- NA
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Background : pregnancy and postpartum period are times of increased risk for deep vein thrombosis (DVT).
Read full original descriptionShow less
The incidence of venous thromboembolic disease (VTE) during pregnancy is estimated at 1-2 per 1,000, and this risk increases in the postpartum period, rising up to 80-fold. VTE is a multifactorial condition, and several studies have identified risk factors for DVT during this period. These factors may be related to the patient herself-such as age, overweight, smoking, a personal or family history of DVT, and/or thrombophilia. Factors related to the pregnancy itself and peripartum events-such as preeclampsia, multiple pregnancy, the mode of delivery (emergency or elective cesarean section), and postpartum hemorrhage-have also been identified as DVT risk factors.
Resistance to activated protein C caused by the Factor V Leiden mutation affects about 5% of the population and, in its heterozygous form, increases the risk of VTE by 3- to 10-fold depending on the study, raising the absolute risk to approximately 1 in 400. The heterozygous mutation of the prothrombin (Factor II) gene affects about 2% of the population and increases the risk of VTE threefold. However, although the risk is increased, the absolute risk of VTE remains low (0.5 to 1%).
Regarding prevention, recommendations are heterogeneous and often based on a low level of evidence. In certain situations (e.g., history of provoked thrombosis, moderate thrombophilia), prophylaxis is not always recommended, or its duration is not clearly defined, and the benefit-risk balance remains uncertain.
The main objective of this study is to describe the duration of anticoagulation prescribed after delivery according to the characteristics of patients carrying these mutations and their mode of delivery. The secondary composite objective is to compare two treatment durations (less than 2 weeks vs. 6 weeks) to determine whether a shorter treatment is less effective in preventing deep vein thrombosis, and whether a longer treatment is associated with more adverse effects.
The target population therefore consisted of adult women carrying an asymptomatic heterozygous mutation of Factor V or Factor II, who had been followed up or had consulted at the Hospices Civils de Lyon for obstetric or hematologic evaluation related to this mutation.
Investigators extracted health data of the included patients from the Hospices Civils de Lyon medical software. They also contacted patients by phone to complete data collection, particularly to determine whether they had experienced a deep vein thrombosis within 12 weeks after delivery, or any adverse effects related to anticoagulant therapy.
The 2 groups in the trial
- 2 weeks or less postpartum thromboprophylaxis
Patients receiving 2 weeks (or less) preventive anticoagulation with low molecular weight heparin after giving birth
Treatment: Retrospective collection of health data and Phone call to every participant
- 6 weeks postpartum thromboprophylaxis
Patients receiving 6 weeks preventive anticoagulation with low molecular weight heparin after giving birth
Treatment: Retrospective collection of health data and Phone call to every participant
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of a Preventive Therapeutic Strategy for Postpartum Venous Thromboembolism in Asymptomatic Women With Heterozygous Factor V Leiden ou Factor II Mutation.
- Record updated
- 6 April 2026